Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine given during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the immunisation safeguards at-risk babies

RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can range from causing mild cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”

The pregnancy vaccine operates by stimulating the mother’s body’s defences to generate defence proteins, which are then transferred to the foetus through the placenta. This maternal immunity provides newborns with immediate protection from the moment of birth, exactly when they are most vulnerable to RSV. The new study shows that protection reaches approximately 85% when the vaccine is administered at least four weeks before delivery. Even shorter intervals between vaccination and birth can still deliver meaningful protection, with evidence suggesting that a two-week gap is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to have the vaccine on schedule, whilst noting that protection can still occur even if given later in the third trimester.

• Nearly 85% protection when vaccinated 4 weeks before birth
• Maternal antibodies passed through placenta safeguard newborns from day one
• Protection possible with 2-week gap before premature birth
• Vaccination in third trimester still provides meaningful infant protection

Compelling evidence from recent research

The effectiveness of the pregnancy RSV vaccine has been confirmed through a thorough investigation undertaken in England, analysing data from close to 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90% of all births during that six-month timeframe, providing comprehensive and reliable evidence of the vaccine’s practical effectiveness. The study’s conclusions have been supported by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The scope of this study gives healthcare professionals and prospective parents with confidence in the vaccine’s demonstrated effectiveness across diverse populations and circumstances.

The results reveal a notable picture of the vaccine’s protective effectiveness. More than 4,500 babies were admitted to hospital with RSV during the study period, with the overwhelming majority being infants whose mothers did not receive the vaccination. This marked difference emphasises the vaccine’s essential role in preventing serious illness in newborns. The reduction in hospital admissions surpassing 80 per cent represents a significant public health achievement, helping to prevent thousands of infants from experiencing the frightening and potentially life-threatening symptoms connected with severe RSV infection. These findings strengthen the importance of the vaccination programme established in the UK in 2024.

Methodology and scope of study

The research analysed birth and hospitalisation records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection levels and hospital admissions. The substantial sample size and thorough nature of the data collection ensured that findings were statistically robust and indicative of the general population, rather than individual cases or small subgroups.

The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to establish the least amount of time between vaccination and birth for optimal protection, as well as to determine whether protection continued to be effective with reduced timeperiods. The methodology assessed actual clinical results rather than controlled laboratory conditions, providing real-world data of how the vaccine performs when given across diverse clinical settings and patient circumstances throughout the final three months of pregnancy.

Learning about RSV and its dangers

Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during busier periods.

The infection triggers deep inflammation in the lungs and airways, making it extremely challenging for vulnerable newborns to feed and breathe effectively. Parents commonly see their babies visibly struggling, their chests rising whilst they work to get enough air into their weakened respiratory system. Whilst most infants improve through supportive care, a small but significant number die from RSV complications each year, making prevention through vaccination a vital health service objective for safeguarding the youngest and most at-risk people in our communities.

• RSV triggers lung inflammation, causing severe breathing difficulties in infants
• Half of all newborns contract the infection during their first few months alive
• Symptoms span from minor cold-like symptoms to serious chest infections that threaten life needing hospital treatment
• More than 20,000 UK babies need serious hospital treatment for RSV annually
• Few infants die from RSV complications each year in the UK

Uptake rates and professional guidance

Since the RSV vaccine programme commenced in 2024, health officials have stressed the value of pregnant women receiving their jab at the optimal time for peak protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has stressed that timing matters greatly for guaranteeing newborns receive the strongest possible immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery delivers approximately 85% protection, experts advise women to receive their vaccine as soon as feasible from 28 weeks of pregnancy forward to maximise the antibodies transferred to their babies via the placenta.

The communication from public health bodies remains clear: pregnant women should make a priority of getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has reassured pregnant women that protection remains still achievable with shorter intervals between immunisation and delivery, including even a two-week gap for those delivering slightly early. This flexible approach acknowledges the practical demands of pregnancy whilst maintaining strong safeguarding for vulnerable newborns during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.

Regional differences in vaccination

Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have varied across different regions and NHS trusts. Certain regions have attained higher vaccination coverage among eligible pregnant women, whilst others continue working to boost understanding and availability of the jab. These geographical variations demonstrate variations in healthcare infrastructure, communication strategies, and community involvement initiatives, though the national data demonstrates consistently strong protection irrespective of geographical location.

• NHS trusts deploying multiple messaging strategies to engage with pregnant women
• Geographic variations in vaccination coverage levels across England demand focused enhancement
• Local healthcare systems tailoring initiatives to meet community needs and circumstances

Practical implications and parent viewpoints

The vaccine’s remarkable effectiveness provides tangible benefits for families across the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV before the rollout of this preventative solution, the 80% decrease in admissions equates to thousands of infants spared from critical disease. Parents no longer face the distressing scenario of seeing their babies gasping for air or struggle to eat, symptoms that define severe RSV infections. The vaccine has markedly changed the picture of neonatal respiratory health, offering expectant mothers a preventative option to shield their youngest infants during those vital initial period.

For families like that of Malachi, whose serious RSV infection led to severe brain damage, the vaccine’s accessibility carries deep personal significance. His mother’s support of the jab emphasises the life-altering consequences that preventable illness can have on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates strongly with parents now offered protection. The knowledge that such significant complications—hospital admission, oxygen dependency, neurological damage—are now largely preventable has provided considerable reassurance to expectant mothers in their late pregnancy, transforming what was once an predictable seasonal threat into a manageable risk.